The combined sales of seven new therapies to treat breast cancer will total nearly $5bn in Europe and Japan by 2019, according to a report by Decision Resources.

Surveyed experts were particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.

A Pharmacor 2010 breast cancer report revealed that Sanofi-Aventis’ PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1bn.

Other key drugs in development include AstraZeneca‘s olaparib and Abbott Laboratories’ veliparib.

Sales of agents targeting HER2-positive breast cancer will increase by almost $2bn billion through to 2019, fuelled by increased uptake of Roche / Chugai’s Herceptin, GlaxoSmithKline’s Tykerb / Tyverb and the approval of Roche / Genentech / Chugai’s trastuzumab-DM1, Roche / Chugai’s Omnitarg and Pfizer’s neratinib.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.